Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

BACKGROUND: Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone a...

Descripción completa

Detalles Bibliográficos
Autores principales: Miner, Jeffrey, Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048659/
https://www.ncbi.nlm.nih.gov/pubmed/27716403
http://dx.doi.org/10.1186/s13075-016-1107-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048659/
https://www.ncbi.nlm.nih.gov/pubmed/27716403
http://dx.doi.org/10.1186/s13075-016-1107-x

Ejemplares similares